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ABSTRACT: The results of quantitative footprinting studies involving the antiviral agent netropsin and a 
DNA-cleaving cationic metalloporphyrin complex are presented. An analysis of the footprinting autora- 
diographic spot intensities using a model previously applied to footprinting studies involving the enzyme 
DNase I [Ward, B., Rehfuss, R., Goodisman, J., & Dabrowiak, J. C. (1988) Biochemistry 27, 1198-12051 
led to very low values for netropsin binding constants on a restriction fragment from pBR-322 DNA. In 
this work, we show that, because the porphyrin binds with high specificity to DNA, it does not report site 
loading information in the same manner as does DNase I. We elucidate a model involving binding equilibria 
for individual sites and include competitive binding of drug and porphyrin for the same site. The free porphyrin 
and free drug concentrations are determined by binding equilibria with the carrier (calf thymus DNA) which 
is present in excess and acts as a buffer for both. Given free porphyrin and free netropsin concentrations 
for each total drug concentration in a series of footprinting experiments, one can calculate autoradiographic 
spot intensities in terms of the binding constants of netropsin to the various sites on the 139 base pair restriction 
fragment. The best values of these binding constants are determined by minimizing the sum of the squared 
differences between calculated and experimental footprinting autoradiographic spot intensities. Although 
the determined netropsin binding constants are insensitive to the value assumed for the porphyrin binding 
constant toward its highest affinity sites, the best mean-square deviation between observed and calculated 
values, D, depends on the choice of (average) drug binding constant to carrier DNA, Kd. Since D as a function 
of Kd passes through a clear minimum, we were able to determine this parameter as well. The study 
demonstrates that the specificity of probe binding to DNA is an important factor influencing the reporting 
of site occupancy by drug in the quantitative footprinting experiment. 
I n  the footprinting experiment, a ligand is allowed to bind 
to a DNA molecule before exposure of the ligand-DNA 
complex to a cleavage agent. From the way in which the 
amount of a particular DNA oligomer produced in the digest 
changes with the amount of ligand added, one can determine 
whether ligand binds at a specific site on the DNA lattice. In 
a quantitative footprinting experiment, one attempts to extract 
values for the equilibrium binding constants of the ligand by 
analyzing the concentrations of DNA oligomers as a function 
of ligand concentration and sequence. 
The most commonly used footprinting agent or probe is the 
DNA hydrolytic enzyme DNase I. Ackers and co-workers 
(Brenowitz et al., 1986a,b; Senear et al., 1986; Carey, 1988) 
have recently reported that this enzyme yields valid individ- 
ual-site isotherms for protein-DNA interactions. While the 
extension of quantitative footprinting techniques to drugs and 
other small ligands appears straightforward, the low binding 
specificities and reduced affinities of these agents complicate 
the extraction of binding constants from footprinting data. 
In recent quantitative studies involving the antiviral agent 
netropsin, a 139 base pair restriction fragment of pBR-322 
DNA, and DNase I, we demonstrated that it is possible to 
obtain drug binding constants as a function of sequence from 
footprinting data (Ward et al., 1988a). After addressing 
DNase I redistribution effects due to drug binding (Ward et 
al., 1988b) and site exclusions due to overlapping binding sites 
on DNA, we analyzed the autoradiographic data associated 
with binding events as well as enhancements, obtaining values 
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for a number of affinity constants for netropsin. The results 
indicated that, although the high-affinity drug sites are all of 
type (AeT),, the presence of the sequence 5’-TA-3’, which 
produces a distortion within the site, (Chuprina, 1987) dis- 
courages netropsin binding to DNA. 
Since quantitative footprinting analysis is certain to have 
a major role in the design and synthesis of new generations 
of sequence-specific drugs (Hurley & Boyd, 1987), it is im- 
portant to more clearly define the scope and limitations of the 
new method. In this work, we examine how the cleavage 
characteristics of the probe affect reporting of valid binding 
information in the footprinting experiment. We carried out 
quantitative footprinting studies of netropsin bound to a 139 
base pair restriction fragment, using, instead of DNase I as 
a cleaving agent, the DNA-cleaving cationic manganese- 
porphyrin complex MnT4MPyP. The different cleavage 
properties associated with the porphyrin lead to substantial 
differences from the previous work. Unlike DNase I, which 
cleaves at many sites on DNA, MnT4MPyP prefers to cleave 
at trinucleotide sequences containing only the bases adenine 
and thymine, Le., (AaT), (Ward et al., 1986, 1987). In ad- 
dition to altered specificity, DNase I and MnT4MPyP exhibit 
different binding and cleavage mechanisms. While the enzyme 
binds to a well-formed minor groove (Suck et al., 1988), the 
metal complex interacts in what appears to be a melted or 
partially melted region of DNA (Raner et al., 1988, 1989; 
Geacintov et al., 1987). Activation of the porphyrin is believed 
to proceed through a high-valent oxo intermediate which at- 
tacks the deoxyribose group, ultimately producing a strand 
break in the polymer (Ward et al., 1986; Bortolini et al., 1986; 
Groves & Nemo, 1983a,b). This behavior contrasts with that 
0 1989 American Chemical Society 
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FIGURE 1: Photograph of autoradiographic data of the netropsin- 
139-mer interaction as probed with MnT4MPyP/oxone. Lane 1 ,  no 
porphyrin control; lanes 2 and 17, DNase I cleavage of the 139-mer 
in the absence of netropsin; lanes 4-15, cleavage by MnT4MPyP/ 
oxone in the presence of various concentrations of netropsin. The drug 
concentrations used (lane 4 highest, lane 15 lowest) can be found under 
Materials and Methods. 
of DNase I, which, through a calcium-dependent reaction, 
catalyzes the hydrolysis of the phosphodiester backbone of 
DNA (Suck et al., 1988). 
MATERIALS AND METHODS 
The 139 base pair HindIII/NciI restriction fragment ob- 
tained from pBR-322 DNA was 3'end labeled at position 33 
with [w3*P]ATP and reverse transcriptase (Lown et al., 1986). 
The numbering system used is the genomic numbering system 
of pBR-322 DNA (Maniatis et al., 1982). Experimental 
protocols for the footprinting experiments and the synthesis 
of MnT4MPyP were as previously described (Ward et al., 
1987; Raner et al., 1988). 
Briefly, all reactions were carried out in 50 mM Tris-HCl 
buffer at pH 7.5 for 20 min at  37 OC. The final DNA con- 
centration in base pairs in each of the 14 reactions was 194 
pM (193 pM sonicated calf thymus DNA and - 1 pM labeled 
fragment). Two control reactions were carried out in the 
absence of netropsin by equilibrating the porphyrin and DNA 
for 30 min in a total volume of 6 pL followed by the addition 
of 2 pL of a 4 mM solution of freshly prepared oxone, KHS05, 
in buffer. The 12 reactions involving netropsin were carried 
out in an identical manner by incubating the drug and the 
porphyrin with DNA for 30 min in 6 pL followed by the 
addition of 2 pL of the activating agent. The final total 
concentration of porphyrin in all experiments was 1.3 pM. 
Final total concentrations of netropsin employed in the various 
experiments were as follows (pM): 1.09, 1 SO, 2.08,2.88,3.99, 
5.52,7.64, 10.6, 14.6,20.3,27.0, and 38.8. After termination 
of the digest, the reaction products were separated in a 12% 
denaturing polyacrylamide gel with a thermostated field 
gradient electrophoresis device developed in-house. The re- 
sulting autoradiogram, Figure 1, was scanned with a linear 
scanning microdensitometer to yield band cross-sectional areas 
(ai = band area for site i) directly proportional to oligo- 
nucleotide concentrations (Dabrowiak et al., 1986). Single 
nucleotide resolution was obtained at  position 45-1 10 with 
lower resolution at positions above 110. Establishment of 
sequence was as earlier described (Lown et al., 1986). 
Careful inspection of the ladder of bands produced by 
porphyrin cleavage relative to those produced by DNase I 
cleavage revealed that the shortest porphyrin oligomer, a 13- 
mer, migrated more slowly, by - 1 nucleotide, than the cor- 
responding DNase I oligomer. The longer oligomers from both 
sources showed a 1 : 1 correspondence in electrophoretic mo- 
bility. Since the ladder of porphyrin-produced bands is not 
complete, as is that produced by DNase I, the lack of corre- 
spondence of the shorter oligomers went unnoticed in earlier 
work involving the porphyrin (Ward et al., 1986,1987), leading 
to an error in sequence assignment for the porphyrin cleavage 
in the region 45-5 1 .  The corrected porphyrin cleavage sites, 
its binding sites, and those of the drug are shown on the se- 
quence of the fragment in Figure 2. 
The 5'-terminal sequence 5'-ATTAAA-3' at positions 38-33 
would be expected to bind both drug and porphyrin. However, 
due to their short lengths, these oligomers migrated from the 
end of the gel into the buffer well, and thus no direct infor- 
5'-AGCTTTAATGCGGTAGTTTATCACAGTTAAATTGCTAACGCAGTCAGGCACCGTGTATGAAATCTAACAA 
3 ' -  AAATTACGCCATCAAATAGTGTCAAIITAACGATTGCGTCAGTCCGTGGCACATACTTTAGATTGTT 
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TGCGCTCATCGTCATCCTCGGCACCGTCACCCTGGATGCTGTAGGCATAGGCTTGGTTATGCCGGTACTGCCG-3' 
ACGCGAGTAGCAGTAGGAGCCGTGGCAGTGGGACCTACGACATCCGTATCCGAACCAA ACGGCCATGACGGC-5' 
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FIGURE 2: Sequence of the HindllI/IVciI 139 base pair restriction fragment of pBR-322 DNA. The asterisk denotes the position of the radiolabel. 
Porphyrin cleavage site (0); porphyrin binding site (hatched bar); netropsin binding site (solid bar). 
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mation on netropsin affinity for this sequence could be ob- 
tained. 
The porphyrin cleavage products appeared to be “clean”, 
and only one band representing each oligomer was detected. 
However, a minor band migrating at position -62 did not 
appear to be part of the porphyrin-produced ladder. Since it 
also appeared on other autoradiograms involving porphyrin 
cleavage of the 139-mer but at a slightly different position, 
it was ignored in the present analysis. The autoradiogram 
showed 90 and 91 to be two distinct bands but the densitometer 
summed the band area for both sites under a single peak 
indexed as 91. Sites 157 and 158, in an unresolved portion 
of the autoradiogram, were indexed as a single site, 157. 
In order to smooth the data for intensity as a function of 
netropsin concentration, the sum of all of the band areas except 
for the full-length band was obtained for each digest. Plotting 
this sum against the total concentration of netropsin present 
in the system showed that addition of drug led to an increase 
in the amount of cleavage on the 139-mer (Figure 3). On 
least-squares fitting the summed areas to polynomial functions 
of D,, the total netropsin concentration, we found the quadratic 
A(D,) = 92.06 + (6.441 X 106)D, - (9.075 X 1010)D,2 (1) 
fit significantly better than the linear function. Cubic and 
higher polynominals gave no improvement in fit. To smooth 
the data and correct for loading errors and differences in digest 
time, each observed site area, ai, was multiplied by the ratio 
of A determined from eq 1 to the experimentally determined 
value of A for the same value of D,. The correction factors 
obtained in this manner were in the range from 0.9 to 1.1. 
Inspection of the control band of uncut fragment on the 
autoradiogram revealed that a small amount of radioactive 
material migrated in the direction of electrophoresis. This 
“bleeding” effect was subtracted from the data by scanning 
the control lane and determining the appropriate area cor- 
rection for a particular band on the autoradiogram. This 
correction, which was greatest for the site nearest the origin 
band site (1  57) ,  was less than 10% of the total area associated 
with the cleavage at this site. 
RESULTS 
From the experiments for zero drug concentration, one can 
immediately identify the preferred porphyrin binding regions 
to be 46-50, 56-62, 65-67, 85-87, 89-92, 94-96, 98-100, 
146-149, and 156-159. These correspond to sequences of at 
least three contiguous A or T bases (Figures 1 and 2). The 
cleavage pattern for a site can be explained if the bound 
porphyrin cuts in the middle of the A-T trimer to which it is 
bound. This is true for isolated trimers as well as for trimers 
which are part of longer A-T sequences. 
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FIGURE 4: Footprinting plots of corrected autoradiographic spot 
intensities versus total netropsin concentration. The site numbers refer 
to the sequence in Figure 2. 
As drug is added to the system, three different types of 
footprinting plots are observed, as illustrated in Figure 4. 
Strong netropsin sites, all of type (A-T),, show rapid decreases 
in intensity with increased drug concentration, Figure 4, site 
61. The observed decrease represents the direct effect of bound 
drug, preventing porphyrin from binding at these sites: the 
classic footprinting phenomenon. The positions for which this 
occurs are 46-50, 56-62,89-92, and 146-149. Sites of type 
(A-T),, 66, 86, 95, 99, and 147, initially show enhanced in- 
tensity with added drug as shown in Figure 4, site 66. How- 
ever, since these sites are weak netropsin binding sites, they 
eventually exhibit inhibition of higher drug concentrations. 
Enhancements also occur for weaker porphyrin binding sites, 
but only for D, in the range from 7.64 to 38.8 pM (see Figure 
4, site 73). These sites are all of the type (AsT)(G.C)~ or 
(A-T) 2( G C )  . 
In order to consider the change in the porphyrin-DNA 
equilibrium as netropsin was added to the system, the amount 
of increase in cleavage at the centers of the isolated (A-T), 
sites ( 6 6 ,  86, 95, 99, and 147) as a function of netropsin 
concentration was calculated. For each site we fit the first 
nine intensities (for D, I 3.99 pM) to quadratic functions of 
drug concentration and divided the slope at D, = 0 by the 
intensity at D, = 0 to obtain the relative enhancement. The 
results (all times were 1.39 f 0.59, 0.68 f 0.47, 0.79 
f 0.70, 3.3 1 f 1.28, and 1.53 f 0.40. Probable errors were 
calculated according to Appendix I found in the supplementary 
material. 
Inspection of the data revealed that in the concentration 
range 0 5 D, I 10.6 pM only the strong drug sites on the 
139-mer were accepting netropsin. In calculating binding 
constants for the strong sites, the intensity data associated with 
15 porphyrin cleavage sites, shown as dots in Figure 2, were 
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used in the analysis. (Data for sites 90 and 91 were taken 
together, as were data for 157 and 158.) Ten of these sites, 
46-50, 56-62, and 89-92, were located within strong netropsin 
sites and behaved like site 61, Figure 4. The other five por- 
phyrin sites, all isolated A-T trimers (66, 86,95,99, and 147), 
were outside of strong netropsin sites, e.g., site 66, Figure 4. 
No weak porphyrin binding sites, e.g., site 73, Figure 4, were 
used in the analysis. The eight different drug concentrations 
plus two digests carried out in the absence of netropsin give 
rise to 150 intensities (concentrations) to be fit by the model. 
ANALYSIS AND MODEL 
Site Exclusions. We consider how a drug molecule, which 
is four nucleotides long, can exclude a porphyrin from its 
trinucleotide binding site. For the isolated drug sites of type 
(A.T), at positions 89-92 and 156-159 (Figure 2), occupancy 
by a netropsin molecule excludes both possible modes of 
porphyrin binding to the tetranucleotide sequence. If a net- 
ropsin site is a contiguous set of base pairs indexed by ( i ,  i+ 1, 
i+2, i+3), where i is the nucleotide location closest to the label, 
porphyrin binding at both ( i ,  i+l ,  i+2) and (i+l,  i+2, i+3) 
is excluded by drug. If the drug binding constant for binding 
to ( i ,  i+l ,  i+2, i+3) is denoted by Ki 
Ki = ci/D0cf (2) 
in which ci is the concentration of sites i at which drug is 
bound, cf is the concentration of free sites i ,  and Do is the 
concentration of free drug. The fraction of site i which is 
occupied by drug, vi, is then given by 
vi = KiDo/ (1 + KiD,) (3) 
Since binding of drug to an isolated tetramer blocks both 
modes of porphyrin binding to the tetramer, the fraction of 
a porphyrin binding site which is free to be occupied by 
porphyrin,f, is the same for both i and i+l ,  i.e. 
Biochemistry, Vol. 28, No. 8, 1989 33 17 
KiDo fi = f i + 1  = 1 - 
1 + KiD, (4) 
The situation with the A-T pentamer at positions 46-50, 
Figure 2, is similar except that drug may occupy two different 
positions within the sequence, either of which excludes the 
binding of the porphyrin to all three of its binding sites within 
the segment. The probability that drug covers the sites from 
i to i+3 is KiDo(l + KiDo + Ki+lDo)-l, and the probability that 
drug covers the sites from i+l to i+4 is KiclD0(1 + KiDo + 
Ki+lDo)-l. Since either situation will prevent the binding of 
porphyrin 
fi = J;.+1 = f i + 2  = 1 - KiDo(l + KiD, + Ki+1D0)-' - 
Ki+lDo(l + KiD, + Ki+lDo)-l = 1/(1 + KiDo + Ki+lDo) 
( 5 )  
For the A-T heptamer, located at  positions 56-62, Figure 
2, the situation is more complicated. The size of netropsin on 
DNA is -4 base pairs and the size of porphyrin -3 base 
pairs, so drug binding to (i+l,  i+2, i+3, i+4) or (i+2, i+3, 
i+4, i+5)  will exclude porphyrin binding to any of its five 
possible binding sites within the sequence ( i  = 56 here). Since 
the probability that no drug is bound to the heptamer is (1 
+ KiDo + Ki+lDo + Ki+2D0 + Ki+3Do)-1, the fraction of the 
three interior binding sites within the heptamer which can bind 
porphyrin is 
3 
i = O  
f;.+l = f;,+z = f i + 3  = (1 + DoCKi+1)-' (6) 
However, it is theoretically possible to have the porphyrin and 
the drug simultaneously occupy the heptamer if the drug is 
bound to ( i ,  i+l, i+2, i+3) while the porphyrin occupies (i+4, 
i+5, i+6). An equivalent situation exists for porphyrin oc- 
cupation of the lowest numbered sites within the heptamer. 
Although electrostatic effects would discourage simultaneous 
occupations on the same DNA restriction fragment (both the 
porphyrin and the drug are cations), it was considered a 
possibility in our analysis in order not to introduce additional 
parameters to describe the anticooperativity. The fraction of 
the first end site which is free of drug is 
2 3 
fi = 1 - D,CK,+,(I + D , C K ~ + ~ ) - I  
i=O i=O 
3 
i=O 
= D&i+3(1 + DoCKi+1)-' (7) 
Si m i 1 a r 1 y 
3 
i=O 
f i + ~  = DoKi(1 + DoCKi+I)-' (8) 
There are no A-T sequences of length greater than seven on 
the HindIII/NciI restriction fragment, and the complications 
just discussed do not occur for A-T segments of smaller length. 
Enhancements. In quantitative experiments involving 
DNase I and netropsin (Ward et al., 1988a,b) addition of drug 
to the system did not cause a change in the total amount of 
cleavage taking place on the 139-mer. This showed that the 
equilibrium between the enzyme and DNA was not disturbed 
during the footprinting titration and that the enhancements 
found in nonbinding regions of the polymer canceled the in- 
hibitions occurring at binding sites. However, the total amount 
of cleavage on the fragment is sensitive to the nature of the 
carrier DNA. If, for example, the carrier is poly(dAdT). 
poly(dAdT), which possesses many more netropsin binding 
sites than the 139-mer, addition of drug causes the enzyme 
to be displaced from the carrier to the fragment. This gives 
rise to an increase in total cleavage similar to that shown in 
Figure 3 for MnT4MPyP (Ward and Dabrowiak, unpub- 
lished). 
The porphyrin cleaves with much higher specificity than 
DNase I. Furthermore, a large fraction of its binding sites 
are also drug binding sites. If the ratios of drug-blocked 
porphyrin sites to free porphyrin sites on the carrier and the 
fragment were the same, total cleavage on the fragment would 
remain constant as drug is added to the system. As is shown 
in Figure 3, this is clearly not the case. Since an increase in 
cleavage is observed, drug must be displacing porphyrin from 
the carrier to the fragment as the titration proceeds. This can 
be easily confirmed by determining the ratio of isolated tri- 
nucleotide sites of type (A-T), to longer contiguous tracts of 
A and T on both the carrier and the fragment. While an 
isolated trimer can bind only porphyrin, the latter type of site 
can bind both the drug and MnT4MPyP. From Figure 2, the 
ratio between the numbers of these two types of site is - 1 for 
the fragment while for calf thymus DNA it can be estimated 
by assuming this carrier is a random arrangement of A.T and 
G.C (see Appendix 2 in the supplementary material), as 
-0.67. Thus, addition of drug to the system will result in a 
release of porphyrin from the carrier, ultimately causing in- 
creased cleavage on the fragment. This mechanism implies 
that the change in the porphyrin-DNA equilibrium can be 
directly monitored via the cleavage increases at  sites of type 
(A-T), on the fragment and that the enhancement due to the 
effect should be the same at  all netropsin binding sites. 
The actual enhancements for sites of type (AeT), on the 
fragment (initial slope divided by intensity for zero drug), given 
3318 
in the previous section, are in fact the same within the esti- 
mated errors (average value = 1.54 f 0.63). The probable 
error in each is as large or larger than the variance, 0.63. 
Further, these enhancements are twice that which should result 
from drug displacement of porphyrin from only the primary 
netropsin sites on the fragment. The enhancement due to such 
displacement is calculable from the number of binding sites 
on the fragment. Finally, a simple redistribution mechanism, 
which was invoked for DNase I (Ward et al., 1988b), would 
give no change in total cleavage with added drug, contradicting 
eq 1. 
Reporting of Site Occupancy by the Cleavage Agent. In 
the quantitative footprinting experiment, the change in the 
amount of cleavage at a particular site is used to measure the 
fraction of that site which is occupied by a drug molecule, vi. 
In studies involving DNase I, it is assumed that the cleavage 
rate at  site i is proportional to 1 - vi or A,, calculated by 
equations like 4-8. This assumption yielded reasonable binding 
constants for netropsin, lac, and trp repressors toward their 
interaction sequences (Brenowitz et al., 1986a,b; Senear, 1986; 
Carey, 1988; Ward et al., 1988a). 
DNase I, unlike MnT4MpyP, binds and cleaves at nearly 
every nucleotide position, so that it acts as if it “sees” a series 
of contiguous binding sites. If the barrier height between sites 
is less than kT, it is possible for the enzyme to easily transit 
in a one-dimensional diffusional process between sites on the 
DNA lattice (Winter & von Hippel, 1981). Effectively, it is 
not bound to a specific site but rather to the entire fragment. 
However, if the probe specificity is high, as is the case with 
MnT4MPyP, the barrier height for transiting from a specific 
site, e.g., an isolated trimer of type (A.T),, to another site 
which binds porphyrin is likely to be high. Then it is appro- 
priate to consider that there is a classic equilibrium between 
unbound cleavage agent and agent bound to a site. In this 
case, the cleavage at a particular site will not be proportional 
to&, as can be shown with a simple example. 
Let Ki and Qi represent the binding constants for drug and 
probe at a site. Let c be the total concentration of such sites, 
P, the total probe concentration, and Db and Pb the concen- 
tration of these sites at which drug and probe, respectively, 
are bound. The cutting rate is proportional to Pb and vi = 
Db/c. The equilibrium expression 
Biochemistry, Vol. 28, No. 8, 1989 Dabrowiak et al. 
timated to be -lo7 M-’ (Geacintov, 1987). Thus, for these 
experiments, the cutting rate should not be proportional to vi. 
We attempted at first to fit the present data using the same 
model employed for analyzing the DNase I experiments, but 
the fit was less good than in previous work (Ward et al., 
1988a). More important, the values found for the drug binding 
constants were all 1-2 orders of magnitude lower than the 
values found previously. It is now clear that this is due to the 
incorrect assumption that the observed cutting rates by the 
porphyrin directly report the fraction of a site which is occupied 
by drug. It is clear from eq 10 that this is not so. 
Role of the Carrier DNA. The concentration of bound 
probe and the concentration of bound drug are determined by 
equilibria like eq 9. When carrier DNA is present in excess, 
equilibria with carrier sites are more important than equilibria 
with sites on the labeled restriction fragment. The equilibria 
with carrier sites then determine free drug and free porphyrin 
concentrations (Of  and P f )  which, through the equilibria with 
fragment sites, determine the bound drug and bound porphyrin 
concentrations. For example, the right side of eq 9 would be 
written as Pb/[Pf(c  - Db - Pb)] and the drug binding equi- 
librium as 
is solved to give 
1 1 
2 2 pb = - C f i  + -Pt + (2Qi)-’ - 
which shows that Pb is not proportional to vi. Expanding the 
square root 
Thus, Pb will be proportional toA. if P, is large compared to 
c and Q;’. This means that, for the footprinting experiment 
to report the fraction of binding site unoccupied by drug, the 
probe binding constant and the amount of probe must be large 
enough to saturate the site with probe. For the experiments 
reported here, c and Pt are -50 pM and 1.3 MM, respectively. 
On the basis of studies involving related porphyrins, the binding 
constant of Mn4MPyP toward calf thymus DNA can be es- 
From a model for the carrier, one can determine Pf and Df  
by considering similar equilibria. 
The increase in cutting rate at  A-T trimers on the labeled 
fragment, as drug is added, is caused by the drug displacing 
the porphyrin from its carrier binding sites to solution. Total 
cleavage on the 139-mer Zt(rt) should increase with total drug 
concentration initially and level off subsequently, when all 
carrier sites which can bind both drug and probe become 
saturated with drug. This is reflected in eq 1 by the negative 
sign of the quadratic term, which leads to a maximum value 
of A of 206.3. When Zt levels off, the free probe concentration 
becomes equal to the total probe concentration minus the 
concentration of probe bound to sites which can bind probe 
but not drug (A-T trimers). The ratio of the amount of 
porphyrin bound to fragment when no drug is present to the 
amount bound when drug saturates all sites on the carrier is 
206.3/92.06 or about 2.3. 
The carrier, calf thymus DNA, is considered to consist of 
a random arrangement of two kinds of sites, A-T bases and 
G-C bases, with a given fraction, p ,  being A-T bases. We 
choosep = 0.6 (Marmur & Doty, 1962) and use probability 
theory to calculate the numbers of various kinds of drug and 
porphyrin sites present in calf thymus DNA: isolated A-T 
trimers, isolated A-T tetramers, etc. (Appendix 2). Given 
values for drug and porphyrin binding constants, free drug and 
free porphyrin concentrations can be calculated for any total 
drug concentration. Note that the carrier serves as a buffer 
for both drug and porphyrin, Le., the binding equilibria for 
the carrier determine the free porphyrin and free drug con- 
centrations, which in turn determine the amounts of drug and 
porphyrin bound to sites on the fragment. 
Our model for the carrier shows that a plot of free porphyrin 
concentration Pf  vs total drug concentration D, is initially 
linear, with positive slope, but the slope decreases afterward 
and the free porphyrin concentration levels off. This is because 
porphyrin continues to bind to A-T trimers, while drug cannot 
bind, while other porphyrin sites become saturated with drug. 
The free drug concentration Df also increases with total drug 
concentration, slowly at first and then linearly, after drug 
binding sites on the carrier are saturated. Figure 5 shows 
Quantitative Footprinting Analysis 
I FIC 
, 
c - 3  
0 
/ 
y - 5  / I 
Biochemistry, Vol. 28, No. 8, 1989 3319 
/ 
-.A' 30 - 
w--.- 
I S  - 4--..:.."-:: L---.-"-.-" .&. ....... - .... 
o . + * ,  , , , I ,  I I ,  i .... . 
1 2  3 4 5  6 7 6 ' 3 1 0 1 1  
T o t a l  Drug Conc. in uM 
FIGURE 5 :  Plot showing the free netropsin concentration (0) and free 
porphyrin concentration (A) as a function of the total netropsin 
concentration. K p  = 1.1 X lo7 M-I; Kd = 3.5 X lo7 M-I; K ,  = 1.0 
X lo6 M-I. 
calculated free porphyrin and free drug concentrations for the 
range of total drug concentrations used in the analysis. The 
asymptotic behaviors (leveling off of Pf, linear dependence of 
Df on 0 , )  are not shown for this range of D,. 
The cutting rate at a site will be assumed to be proportional 
to the concentration of porphyrin at  that site, as calculated 
from the appropriate competitive binding equilibrium ex- 
pression and the free drug and free porphyrin concentrations 
Df and Pf. These concentrations, calculated by considering 
equilibria with carrier sites, detailed in Appendix 2, depend 
on the values of the drug and porphyrin binding constants to 
carrier sites. Like the binding constants to fragment sites, the 
binding constants to carrier sites will be determined to give 
the best fit of calculated to experimental footprinting data. 
Cutting Rates. For an isolated A-T trimer, the cutting rate 
is proportional to K$f(l + K$f)-'. An A-T tetramer on the 
fragment can bind either drug (binding constant Ki) or por- 
phyrin (in two ways), so that the cutting rate at either interior 
position is proportional to 
xP = KpPf(l + 2K$f + KiDf)-' (12) 
There can be no cutting at the end positions according to our 
model. An A-T pentamer can bind either drug or porphyrin, 
the former in two ways and the latter in three ways, so that 
the cutting rate at any of the three interior positions is pro- 
portional to 
xP = KpPf(l + 3K$f + KjDf + Ki+iDf)-' (13) 
Here, Ki and Ki+l are binding constants for the two overlapped 
drug binding sites. The constants for the individual sites cannot 
be determined according to eq 13.  
The heptamer corresponding to A-T's at  positions i to i + 
6 (i = 56) can bind one or two porphyrins, or a drug molecule 
and a porphyrin, and cutting can take place at  positions i + 
1 to i + 5 .  Considering all the situations, we find the cutting 
rate at  i + 1 to be proportional to 
x p  = [K$f + 4(K$d2 + K$fKi+@fI / [1 + 5KpPf + 
6(KppfIz + (Ki+1 + Ki+2 + Kif3 + Ki+dDf + 
K$f(Ki+, + Ki+4)Dfl (14) 
where Ki+' to Ki+4 are the four drug binding equilibrium 
constants associated with drug binding to the heptamer. For 
the cutting rate at i + 5, Ki+4 and Ki+' are interchanged in 
eq 14. Cutting at  i + 2 is proportional to 
x c  = [Kppf + 2(Kppfl2I/[1 + 5K$f + 6(K$d2 + (Ki+l + 
Ki+2 + Ki+3 + Ki+4)Df + K$f(Ki+l + Ki+dDfl (15) 
and the same expression describes cutting at i + 4. For cutting 
at i + 3, the porphyrin must occupy positions i + 2 ,  i + 3, and 
i + 4 and no other porphyrin or drug can then bind, so the 
rate is proportional to 
According to eq 14-16, the individual values of Ki+2 and Ki+, 
cannot be determined, but just their sum. 
On first attempting to fit experimental intensities with this 
model, we found that there were large discrepancies between 
the theoretical and experimental points for the highest drug 
concentration used, 10.58 pM. With an effective concentration 
of primary sites of type (A.T)4 present in the system of - 10" 
M (see Appendix 2), the carrier would be saturated by drug 
before Dt = 10.58 pM, causing Df to increase rapidly with Dt. 
This would give a sharp decrease in fragment cutting rates 
with D,, which was not experimentally observed. Thus, there 
are other (weaker) drug binding sites on the carrier which keep 
the free drug concentration low at higher values of total drug 
concentration. Previous footprinting studies by us (Ward et 
al., 1988a) have shown that these weak sites are probably 
tetramers including one G or C .  To take them into account, 
we assume that, in addition to strong binding sites, the carrier 
possesses weak drug binding sites at a concentration twice that 
of A-T trimers, which are one kind of weak netropsin site. The 
netropsin binding constant for these weak sites, K,, is at least 
2 orders of magnitude lower than the binding constants for 
the strong sites (107-10s M-I). The precise value of K,, as 
might be expected, does not significantly affect the determined 
values of binding constants for the strong sites; it only helps 
improve the fit between calculated and experimental intensities 
at  a few points (for the highest drug concentration) in the 
entire data set. 
CALCULATION OF BINDING CONSTANTS 
Assuming values for Kp, K,, and Kd and using the statis- 
tically determined concentrations of A-T trimers, tetramers, 
..., octamers on the carrier, and weak drug sites on the re- 
striction fragment, we can calculate free drug and free por- 
phyrin concentrations for each known total drug concentration 
by solving the simultaneous equations for carrier equilibrium 
(Appendix 2). The resulting values for free porphyrin and free 
drug concentrations, Pf and Df, are used with values for the 
Ki to compute the amount of porphyrin bound at  each site on 
the labeled fragment, and hence the footprinting autoradio- 
graphic spot intensities for comparison with experimental in- 
tensities. The binding constants for drug molecules on frag- 
ment sites are then chosen to minimize the sum of the squared 
deviations between experimental and calculated spot intensities. 
Initially, the value of the porphyrin binding constant to sites 
of type (A-T),, Kp, was chosen as 1 X lo7 M-'. Various values 
for Kd (drug binding constant to carrier) were used, as dis- 
cussed below. In our previous calculation (Ward et al., 1988a), 
we assumed a concentration of drug sites on the carrier of 190 
pM and determined a binding constant for these sites of 1 X 
lo6 M-', which represents an average between the constants 
for strong sites and others. Since the strong-site concentration 
for the present calculation is - 17 pM (see Appendix 2), the 
value of Kd should be about 1 . 1  X lo7 M-'. As pointed out 
previously, it is the product of Kd and the site concentration 
that is important. The total porphyrin concentration Pt, 
measured optically, was 1.3 pM in all the experiments con- 
sidered here, while Dt, the total netropsin concentration, varied 
from 0 to about 10 pM. 
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FIGURE 7: Experimental (0 )  and calculated (0) footprinting plots 
for various binding and enhancement sites on the 139-mer. Kp = 1 
The site binding constants for drug on the fragment are 
determined by searching, using the simplex search algorithm 
(Fletcher, 1980), for the set which minimizes the sum of the 
squared deviations between the experimental and calculated 
spot intensities. For any set of values for Kd, Kp, and K,  the 
algorithm converges properly to yield the set of Ki which 
minimizes: 
X IO' M-I; Kd = 3.5 X lo7 M-'; K, = 1.0 X lo6 M-'. 
D = CCCZjj - l j j ) 2  (17) 
i j  
where Zii is the experimental intensity for site i at thejth total 
drug concentration and is the corresponding calculated value. 
The resulting mean-square deviation, D, is smaller than what 
we obtained with the earlier study involving DNase I as a 
footprinting probe (Ward et al., 1988a). Due to the sizes of 
the porphyrin and the drug when bound to DNA, the cut- 
ting-rate expressions do not allow the determination of all Ki, 
but only K46 + K47, KS6, K57 + KSS,  K s ~ ,  Ka9, and K156. 
nucleotide sequence 
positionb of site MnT4MPyP DNase IC 
46 + 47 7.8 9 8d 
56 M T T  0.4 0.3 0.2d 
57 + 58 xel 26 18 20d 
7TAA 
59 lTM 1.4 13 7d 
89 n-TA 5.3 14 1 Od 
156 E% 2.1 8 I d  
AATT 
AAAT 
"Values were determined with Kd = 3.5 X lo7 M-I, Kp = 1.0 X IO7 
M-I, and K,  = 1.0 X IO6 M-I. bThe position of the lowest numbered 
nucleotide of the tetramer binding site is given, see Figure 2. cData 
from Ward et al. (1988a). dCarrier-free experiment. 
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Figure 6 is a plot of the lowest value of D found for various 
choices of Kd, the netropsin binding constant to the carrier. 
It is seen that there is a clear minimum for Kd - 3.5 X lo7 
M-'. The value of Kd is thus determined, like the values of 
Ki, by minimization of D in eq 17. In Table I, we give the 
Ki values corresponding to this minimum and compare them 
with the values found by analysis of DNase I footprinting data. 
The experimental intensities are compared with the calculated 
ones for the "best fit" in Figures 7 and 8 (Ward et al., 1988a). 
As is evident from Table I, the netropsin binding constants 
obtained with DNase I and MnT4MPyP are in the same rank 
order and are in generally good agreement with regard to 
magnitude. The site with the lowest binding constant, 56, 
contains the sequence 5'-TA-3' which is expected to produce 
a distortion in the minor groove of DNA (Calladine, 1982). 
Although further study will be necessary, this distortion likely 
produces less than optimum drug-DNA contacts, leading to 
a decrease in the binding constant of netropsin. Agreement 
between the DNase I and MnT4MPyP data appears poorest 
for site 59. Since this site is in a heavily overlapped region 
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competitive binding of drug and porphyrin at specific sites on 
both the fragment and carrier DNA present. Analysis ac- 
cording to this model also yields site-specific binding constants 
for netropsin in good agreement with previously determined 
values. 
While the high specificity of MnT4MPyP prevents it from 
being a “broad spectrum” footprinting probe useful for stud- 
ying ligands of unknown specificity, it can be used to measure 
binding constants for drugs with affinities for AT sites. In 
this respect it is similar to the AT-specific compound Cu(o- 
phen)* which has been used in footprinting experiments in- 
volving netropsin and the duplex d(CGCGAATTCGCG)* 
(Kuwabara et al., 1986). From the present study and earlier 
published experimental (Ward et al., 1988a) and theoretical 
work (Goodisman & Dabrowiak, 1985), it is clear that the 
detailed mechanism by which the probe binds and cleaves 
DNA is unimportant for reporting valid binding information 
for the drug. While DNase I catalyzes a phosphodiester hy- 
drolysis of the DNA backbone, the porphyrin cleaves DNA 
via an oxo intermediate which appears to attack the deoxy- 
ribose moiety of the polymer. It is the specificity of the probe 
and not its mechanism of binding or cutting, per se, which 
needs to be addressed in obtaining information on site occu- 
pancy in the quantitative experiment. This point has recently 
been reinforced by preliminary results of quantitative foot- 
printing experiments involving Fe-MPE (Dabrowiak and 
Goodisman, unpublished results). This intercalating complex 
cleaves DNA via radical release but, like DNase I ,  exhibits 
relatively low DNA sequence specificity. Despite the dramatic 
differences in cleavage mechanism, both the enzyme and 
Fe-MPE can be analyzed with the DNase I type redistribution 
model to yield valid binding constants for ligands bound to 
DNA. 
When carrier DNA is present in excess, as is the case for 
the results considered here, it serves as a buffer for both drug 
and probe. While its presence in the experiment was initially 
viewed as a complication, it allows the determination of net- 
ropsin binding constants, K,, without direct knowledge of the 
parameter Kp, the porphyrin binding constant toward its in- 
teraction sequences. The values of the Ki as well as the 
mean-square deviation D (Figure 9) are independent of Kp for 
Kp > - lo6 M-’. 
As before (Ward et al., 1988a), the binding of drug to DNA 
was assumed to occur in an independent noncooperative 
fashion. This assumption was included in the model used for 
analysis for two reasons. First, netropsin is a groove-binding 
drug, and unlike intercalators, it binds without greatly dis- 
torting DNA. Without distortion the possibility that affinities 
for adjacent binding sites would be altered through allosteric 
effects was considered remote. Also, only the early loading 
events on the polymer were used in the analysis. Thus, al- 
though many strong netropsin sites are present on the 139-mer, 
only a relatively small fraction of the fragments present in the 
reaction medium possess more than one bound drug molecule 
in the concentration range studied. 
Although the porphyrin concentration used in the work was 
relatively low, about one porphyrin per fragment, the possibility 
exists that porphyrins bound to nearby drug sites would in- 
fluence the binding constant of the drug for those sites. 
However, the generally good agreement between binding 
constants derived from DNase I and MnT4MPyP, which have 
radically different binding mechanisms, suggests that the 
porphyrindrug cooperative effects are probably small and not 
detectable with the present data. A possible exception may 
be the site at 89 which is flanked by two porphyrin binding 
\ 
*... ............. *......*...... ...... ................””......... ......... 
**\. 
I I I 
(Appendix 2, eq 11) involves only the product Kff, so doubling 
the assumed value of Kp simply divides all of the calculated 
values of Pf by 2. The same Kp is used for the fragment as 
for the carrier, and only K T f  enters eq 12-16. Thus, if Kp 
> -lo6 M-l, it is unimportant to know its exact value in 
calculating valid binding constants for the drug bound to its 
interaction sequences. 
CONCLUSIONS 
In this paper we have examined the ability of the AT-specific 
cleaving agent MnT4MPyP to report valid binding information 
for netropsin bound to a 139 base pair restriction fragment 
of pBR-322 DNA. The reporting of site occupancy by the 
porphyrin is different from that of DNase I. The behavior 
of the latter may be understood by considering that DNase 
I “sees” a closely spaced collection of sites on DNA with 
comparable binding constants. The potential surface involves 
closely spaced minima, so the barrier to movement from one 
site to its neighbor cannot be very large and the enzyme can 
be thought of as being bound to the fragment as a whole rather 
than to a specific site on the fragment. On the other hand, 
the porphyrin complex “sees” a few well-separated minima, 
so that it is appropriate to consider binding equilibria for 
individual sites on the fragment. As we have shown, analysis 
of the porphyrin data using the model developed for DNase 
I leads to equilibrium constants for netropsin which are several 
orders of magnitude lower than those previously determined 
(Ward et al., 1988a). The redistribution model employed for 
DNase I is also incapable of explaining the increase in the total 
amount of cleavage on the fragment with added drug, or the 
magnitude of the drug-induced enhancement in cutting rate 
at sites where netropsin cannot bind. These are explained 
naturally in the model presented above, which considers 
3322 Biochemistry, Vol. 28, No. 8, 1989 
sites. Occupancy of these flanking sites by MnT4MPyP may 
produce a distortion within the netropsin site causing the 
binding constant for this site to be lower than that obtained 
with DNase I, Table I. 
The method described in this paper utilizes only the auto- 
radiographic spot intensities derived from footprinting ex- 
periments and certain easily measured concentrations to de- 
termine drug binding constants as a function of sequence on 
natural DNA. The success of the approach depends on col- 
lecting intensity data for many sites on a DNA polymer. Since 
the number of experimental points is much larger than the 
number of parameters (binding constants) characterizing the 
loading events, a minimization approach can be used to cal- 
culate individual-site binding constants for ligands. Although 
the full scope and limitations of quantitative footprinting are 
yet to be defined, the method is clearly superior to conventional 
techniques which yield average rather than site-specific iso- 
therms for ligand binding to a DNA lattice. 
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